HEMLIBRA 150 mg/ml, solution for injection bottle, 0.4 ml
Active ingredients: Emicizumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 0.4 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- HEMLIBRA 150 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon en verre de 0,4 ml
- Marketing authorisation holder
- ROCHE REGISTRATION (ALLEMAGNE)
- Reimbursement according to BDPM
- 100%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Prévention des saignements chez les personnes atteintes d'hémophilie A (maladie qui rend le sang plus liquide et favorise les hémorragies à cause d'un manque de Facteur VIII dans le sang) :<br>dans certains cas sévères de la maladie. ; JOURNAL OFFICIEL ; 26/05/21
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 13 Feb 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61529993CIP73014142CIP133400930141427Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉMICIZUMABsolution | 150 mg · 1 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.